



PRESS RELEASE

Appointment of Claire Giraut as bioMérieux's Corporate Vice President & Chief Financial Officer

Marcy l'Etoile, France, January 27, 2014 — bioMérieux, a world leader in the field of *in vitro* diagnostics, announces that Claire Giraut has been appointed Corporate Vice President & Chief Financial Officer.

Claire Giraut joined bioMérieux's Management Committee in September 2013 as Head of the Purchasing and Information Systems departments. Since January 1st, she has also been appointed Corporate Vice-President & Chief Financial Officer of the Group, succeeding Henri Thomasson.

A graduate of France's Institut National Agronomique Paris-Grignon, Claire Giraut has held various positions of responsibility in finance for most of her professional career. After beginning her career with the Sanders Group followed by the Serete Group, in 1997 she was appointed Chief Financial Officer and Head of Communications of the Coflexip Stena Offshore Group, which was at the time world leader in subsea oil field services. She was subsequently Chief Financial Officer of the Offshore branch and member of the Management Board of Technip, following its merger with Coflexip in 2002. For the next eight years, Claire Giraut was Chief Financial Officer at Ipsen, where she notably headed up the group's Initial Public Offering. In her most recent assignment up to spring 2012, she was Chief Financial Officer at Europcar Groupe S.A.

In parallel with her role in bioMérieux, Claire Giraut is a member of the Board of Directors of Julius Baer Group Ltd., an international private banking group, headquartered in Zurich, Switzerland. She is also a member of the Board of Directors of Heurtey Petrochem, an international oil and gas engineering group based in Vincennes (France).

About bioMérieux

Pioneering Diagnostics

A world leader in the field of *in vitro* diagnostics for 50 years, bioMérieux is present in more than 150 countries through 41 subsidiaries and a large network of distributors. In 2013, revenues reached €1,588 million with 87% of sales outside of France.

bioMérieux provides diagnostic solutions (reagents, instruments, software), which determine the source of disease and contamination to improve patient health and ensure consumer safety. Its products are used for diagnosing infectious diseases and providing high medical value results for cancer screening and monitoring and cardiovascular emergencies. They are also used for detecting microorganisms in agri-food, pharmaceutical and cosmetic products.

bioMérieux is listed on the NYSE Euronext Paris market (Symbol: BIM – ISIN: FR0010096479).
Corporate website: www.biomerieux.com

Contacts

Media Relations

bioMérieux

Aurore Sergeant
Tel: + 33 4 78 87 54 75
media@biomerieux.com

Image Sept

Laurence Heilbronn
Tel: + 33 1 53 70 74 64
lheilbronn@image7.fr

Claire Doligez
Tel: + 33 1 53 70 74 48
cdoligez@image7.fr